### Epidemiology of SARS-CoV-2 Emergence Amidst Community-Acquired Respiratory

2 Viruses

1

8

- 3 Karoline Leuzinger<sup>1,2</sup>, Tim Roloff<sup>3,4</sup>, Rainer Gosert<sup>1</sup>, Kirstin Sogaard<sup>3,4</sup>, Klaudia Naegele<sup>1</sup>,
- 4 Katharina Rentsch<sup>5</sup>, Roland Bingisser<sup>6</sup>, Christian H. Nickel<sup>6</sup>, Hans Pargger<sup>7</sup>, Stefano
- 5 Bassetti<sup>8</sup>, Julia Bielicki<sup>9</sup>, Nina Khanna<sup>10</sup>, Sarah Tschudin Sutter<sup>10</sup>, Andreas Widmer<sup>10</sup>,
- 6 Vladimira Hinic<sup>14</sup>, Manuel Battegay<sup>10</sup>, Adrian Egli<sup>3,4,+</sup>, Hans H. Hirsch<sup>1,2,10+</sup>
- 7 + equal contribution
- <sup>1</sup> Clinical Virology, Laboratory Medicine, University Hospital Basel, Basel, Switzerland
- <sup>2</sup> Transplantation & Clinical Virology, Department Biomedicine, University of Basel, Basel,
- 11 Switzerland
- 12 <sup>3</sup> Applied Microbiology Research, Laboratory Medicine, Department Biomedicine, University
- 13 of Basel, Basel, Switzerland
- <sup>4</sup> Clinical Bacteriology and Mycology, Laboratory Medicine, University Hospital Basel, Basel,
- 15 Switzerland
- 16 <sup>5</sup> Clinical Chemistry, Laboratory Medicine, University Hospital Basel, Basel, Switzerland
- 17 <sup>6</sup> Emergency Medicine, University Hospital Basel, Basel, Switzerland
- 18 Thtensive Care Unit, University Hospital Basel, Basel, Switzerland
- 19 8 Internal Medicine, University Hospital Basel, Basel, Switzerland
- <sup>9</sup> Pediatric Infectious Diseases & Hospital Epidemiology, University Children Hospital Basel,
- 21 Basel, Switzerland

23

25

- 22 <sup>10</sup> Infectious Diseases & Hospital Epidemiology, University Hospital Basel
- 24 Short Title Epidemiology of SARS-CoV-2 and CARVs
- 26 **Keywords** COVID-19, respiratory virus, multiplex, nucleic acid testing, co-infection

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 **Conflict of interest statement** 28 All authors: none to declare. 29 30 **Funding statement** 31 This work was supported by the Clinical Virology Division and the Clinical Bacteriology and 32 Mycology Division, Laboratory Medicine, University Hospital Basel, Basel, Switzerland, and 33 an appointment grant to HHH, Department Biomedicine, University of Basel, Basel, 34 Switzerland. 35 36 **Corresponding author contact information** 37 Hans H. Hirsch, MD MSc 38 Transplantation & Clinical Virology 39 Department Biomedicine 40 University of Basel 41 Petersplatz 10 42 4009 Basel, Switzerland 43 Phone: +41 61 328 6697 44 Email: hans.hirsch@unibas.ch

45 Abstract 46 Background. SARS-CoV-2 emerged in China in December 2019 as new cause of severe 47 viral pneumonia (CoVID-19) reaching Europe by late January 2020. We validated the WHO-48 recommended assay and describe the epidemiology of SARS-CoV-2 and community-49 acquired respiratory viruses (CARVs). 50 Methods. Naso-oropharyngeal swabs (NOPS) from 7663 individuals were prospectively tested by the Basel-S-gene and the WHO-based E-gene-assay (Roche) using Basel-N-52 gene-assay for confirmation. CARVs were tested in 2394 NOPS by multiplex-NAT, including 53 1816 together with SARS-CoV-2. 54 **Results.** Basel-S-gene and Roche-E-gene-assays were concordant in 7475 cases (97.5%) 55 including 825 (11%) positive samples. In 188 (2.5%) discordant cases, SARS-CoV-2 loads 56 were significantly lower than in concordant positive ones and confirmed in 105 NOPS. Adults were more likely to test positive for SARS-CoV-2, while children were more likely to test 58 CARV-positive. CARV co-infections with SARS-CoV-2 occurred in 1.8%. SARS-CoV-2 59 replaced other CARVs within 3 weeks reaching 48% of all detected respiratory viruses 60 followed by rhino/enterovirus (13%), influenzavirus (12%), coronavirus (9%), respiratory syncytial (6%) and metapneumovirus (6%). 62 Conclusions. The differential diagnosis for respiratory infections was broad during the early 63 pandemic, affecting infection control and treatment decisions. We discuss the role of pre-64 existing immunity and competitive CARV replication for the epidemiology of SARS-CoV-2 65 infection among adults and children. 66

### **Abstract Word Count: 200**

51

57

61

#### Background

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in China during winter 2019 as new cause of severe viral pneumonia called coronavirus infectious disease (CoVID)-19 [1, 2]. Since late January 2020, SARS-CoV-2 continues to spread across the world including Europe [1, 3]. By the end of May 2020, the WHO reported more than 5 million confirmed SARS-CoV-2 cases, 400 thousand deaths of which approximately one third occurred in Europe [4]. The first case in Switzerland was diagnosed on 25 February 2020, reaching peak rates by the end of March before plateauing at approximately 30'000 confirmed cases by the end of April 2020 (https://covid-19-schweiz.bagapps.ch/de-2.html). Notably, the initial pandemic spread of SARS-CoV-2 occurred in the winter months of the Northern hemisphere, during which several community-acquired respiratory viruses (CARVs) are known to circulate including influenzavirus-A/B, respiratory syncytial virus, metapneumovirus, parainfluenzavirus, and human coronaviruses. Although the progression of SARS-CoV-2 infection to severe lower respiratory tract infectious disease (RTID) is unprecedented, all CARVs are known to significantly contribute to seasonal excess morbidity and mortality in immunocompetent and immunocompromised populations [5]. In fact, CARV-RTID presents clinically as an influenza-like illness defined as at least one respiratory and one systemic symptom/sign such as cloqued or runny nasal airways, sore throat, cough, fatigue, fever, myalgia [5], which may be indistinguishable from early stages of SARS-CoV-2 infection [6], while dysgeusia appears to be rather prominent. Thus, a broad diagnostic approach using multiplex nucleic acid testing (NAT) may be important. Notably, the course and impact of SARS-CoV-2 on circulating CARVs has not been fully characterized. Early reports suggested that co-infections with SARS-CoV-2 and other CARVs were rather uncommon in immunocompetent adults [7]. However, a recent study reported co-infection of CARVs and SARS-CoV-2 at rates of 5% including influenzavirus-A/B, respiratory syncytial virus and rhinoviruses [8]. Here, we report on the epidemiology of SARS-CoV-2 infection and other CARVs during the early pandemic peak in Northwestern Switzerland from January 1 until March 29, 2020.

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

Methods Patients and samples Patients presenting with influenza-like illness to the outpatient department or emergency department of the University Hospital Basel or the University of Basel Children's Hospital were enrolled in this analysis of prospectively collected results on respiratory virus panel and/or SARS-CoV-2 testing between 1. January and 29. March 2020. Clinical samples and total nucleic acid extraction For sampling, two swabs from the naso- and oropharyngeal sites (NOPS), respectively, were taken and combined into one universal transport medium tube (UTM, Copan). In smaller children, only nasopharyngeal swabs were taken. Total nucleic acids (TNAs) were extracted from the UTM using the MagNA Pure 96 system and the DNA and viral NA small volume kit (Roche Diagnostics, Rotkreuz, Switzerland) or using the Abbott m2000 Realtime System and the Abbott sample preparation system reagent kit (Abbott, Baar, Switzerland). SARS-CoV-2 reverse transcription quantitative nucleic acid testing TNAs were tested for SARS-CoV-2 RNA using a laboratory-developed reverse transcription quantitative nucleic acid test (RT-QNAT) targeting specific viral sequences of the spike glycoprotein S-gene (Basel-SCoV2-S-111bp; Supplementary Table 1) and a commercial RT-QNAT targeting the viral envelope gene (E-gene; Roche). For the Roche assay, the extraction control was included as specified by the manufacturer, while Basel assays were spiked with unrelated nucleic acids. Both assays were run on independent plates in parallel for all NOPS tested. Concordant negative results were interpreted as confirmed, while concordant positive and discordant results were retested with a laboratory-developed RT-QNAT targeting the viral nucleocapsid gene (Basel-SCoV2-N-98bp; Supplementary Table 1). The Roche-E-gene was run on the CFX96 RT-PCR (Bio-Rad Laboratories, Cressier, Switzerland) as specified by the manufacturer. The Basel-SCoV2-S-111bp and Basel-SCoV2-N-98bp used the RT Takyon MMX containing uridine and the uracil-N-glycosylase

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

for amplicon decontamination (Eurogentec, Liège, Belgium), 300 nmoles end concentration of the primers and probe for the Basel-S-gene RT-QNAT, and 900 nmoles end concentration of the primers and 100 nmoles probe for the Basel-SCoV2-N-98bp RT-QNAT (Supplementary Table 1). The Basel assays had a reaction volume of 25 μL and 5 μL of extracted TNA run on an ABI7500 Fast Real-Time PCR system (Thermo Fisher Scientific, Massachusetts, United States). The single-step reverse transcription and cycling conditions for the RT-QNATs were 50 °C for 10 min; 95 °C for 5 min; and 45 cycles of 95 °C for 30 s and 60°C for 60 s. Phylogenetic analysis of SARS-CoV-2 genome sequences SARS-CoV-2 complete genome sequences (N=3323), the S-gene and N-gene sequences were downloaded from the NCBI-GenBank and GISAID database (https://www.gisaid.org/; accessed on 20th of April). Sequence alignments were performed with the CLC Genomic Workbench software (version 12; QIAGEN, Hilden, Germany). Divergences were estimated by the Jukes-Cantor method, and neighbor-joining trees were visualized with the CLC Genomic Workbench software. In addition, the frequency of single nucleotide polymorphisms (SNPs) was assessed in the S-gene and N-gene RT-QNAT target regions with the basic variant detection tool of the CLC Genomic Workbench software and a viral reference genome (acc. no. NC 045512; Supplementary Table 2) as described previously [9]. Biofire Filmarray respiratory panel The qualitative multiplex NAT respiratory panel used 200 µL of UTM in the Torch system (Biofire Filmarray respiratory 2.0 panel, bioMérieux) covering influenzavirus (IV)-A (A/H1, A/H1-2009, A/H3), IV-B, human respiratory syncytial virus (HRSV)-A/B, adenovirus (HAdV), human metapneumovirus (HMPV), rhinovirus/enterovirus (HRV), parainfluenzavirus (HPIV) 1-4 (as separate targets), human coronavirus (HCoV)-NL63, -229E, -OC43, -HKU1, -middle east respiratory syndrome (MERS)-CoV, Bordetella pertussis, B. parapertussis, Chlamydophila pneumonia, and Mycoplasma pneumoniae.

Statistics and graphical presentations

All statistical data analysis was done in R (https://www.r-project.org/), and Prism (version 8;

Graphpad Software, CA, USA) was used for data visualization. Statistical comparison of
non-parametric data was done using Mann–Whitney U test, and Bonferroni correction was
applied for multiple comparisons.

Ethics statement

The study was conducted according to good laboratory practice and in accordance with the
Declaration of Helsinki and national and institutional standards and was approved by the
ethical committee (EKNZ 2020-00769).

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

Results To independently evaluate the WHO-recommended assay, we designed two different single step RT-QNAT assays targeting the S-gene and the N-gene. We observed close clustering of the complete SARS-CoV-2 genomes and specifically its S- and N-gene target sequences, clearly separating from the corresponding HCoV genome sequences (Supplementary Figure 1). We found no insertions or deletions in either target, and only a single SNP in the probe-binding site of the S-gene RT-QNAT in one of 3323 (0.03%) sequences, at a central position not predicted to affect the assay performance (Supplementary Table 2). To cross-validate the WHO-Roche-E-gene and the Basel-S-gene without reporting delay, we analyzed all submitted NOPS directly in parallel. From 9<sup>th</sup> until 29<sup>th</sup> of March 2020 (calendar week 11 to 13), 7663 samples were submitted from 354 (5%) pediatric and 7309 (95%) adult patients (**Table 1**). Most patients had presented to primary care and outpatient clinics (74%). while 26% of cases originated from secondary and tertiary care units including 3% from intensive care (Table 1). The Basel-S-gene and the Roche-E-gene RT-QNATs were concordant in 7475 (97.5%) samples, consisting of 6650 (86.8%) negative and 825 (10.7%) positive cases, all of which were independently confirmed by the N-gene assay (Supplementary Figure 2). In 188 (2.5%) cases, discordant results were obtained consisting of 170 (2.2%) Basel-S-gene positive/ Roche-E-gene negative, and 18 (0.2%) Basel-S-gene negative/Roche-E-gene positive cases. The N-gene RT-QNAT confirmed 102/170 (60%; overall 1.3%) of the former, but only 3 (0.04%) of the latter (**Supplementary** Figure 2). Cycle threshold (Ct)-values were significantly lower in these samples, indicating a higher viral load for concordant positive than for discordant results (median, S-gene RT-QNAT: 23.6 vs. 36.8 vs. 37.1; P<0.001; Figure 1A). Indeed, 666 (72%) NOPS extracts had SARS-CoV-2 loads of more than 1 million copies (c)/mL UTM in the S-gene RT-QNAT (median 7.2 log<sub>10</sub> c/mL, IQR 5.8 – 8.4; **Figure 1B**). Conversely, the Ct-values were significantly higher for discordant results indicating low viral loads (Figure 1A). Thus, the Basel-SCoV2-S-111bp had a sensitivity of 99.7% (95% CI: 95% - 100%) and specificity of

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

99.0% (95% CI: 91% - 100%). Taken together, 930 (12.1%) SARS-CoV-2 infections were confirmed and further analyzed. Among SARS-CoV-2-positive patients, male gender was more prevalent (49% vs. 44%; p=0.002) and the median age was higher (49 vs. 43 years; p<0.001) compared to those with a negative test result (**Table 1**). However, higher patient age was not associated with higher SARS-CoV-2 loads (Spearman's r=0.034, p=0.30). Moreover, SARS-CoV-2 was detected in 14 (4%) of 354 children compared to 916 (12%) of the non-pediatric patients (p<0.05). To investigate the epidemiology of CARVs and SARS-CoV-2 during the first phase of the pandemic, we identified all NOPS (n=2394) from patients with influenza-like illness, which had been tested by CARV-multiplex-NAT between January 1st (calendar week 1) and March 29<sup>th</sup> 2020 (calendar week 13). In 942 (39%) cases, at least one pathogen had been detected including 95 with two (3.9%), and 9 with 3 (0.1%) pathogens. The weekly prevalence rates for SARS-CoV-2 and CARVs revealed a fluctuating CARV activity until calendar week 7 followed by a steep increase in CARVs, which declined after week 10, when SARS-CoV-2 detection rates rose sharply (Figure 2A). This was also reflected in the cumulative rates (Figure 2B; histogram) reaching 48% for SARS-CoV-2 by calendar week 13, followed by rhinovirus (13%) and influenzavirus (12%) (Figure 2B; pie chart). Restricting the analysis to 1816 NOPS, from which both, CARV-multiplex-NAT and SARS-CoV-2 RT-QNAT had been requested, the cumulative SARS-CoV-2 detection was 17% after rhinovirus (22%) and influenzavirus (20%) (Figure 2C; pie chart). The weekly detection rates revealed that SARS-CoV-2 largely replaced all other CARVs except rhinovirus (Figure 2C). Unlike for SARS-CoV-2, the CARV detection rate was significantly higher in children than in adults (P<0.001; Table 2). This significant effect also prevailed when SARS-CoV-2 and CARV positive cases where analyzed together and when excluding rhinovirus-infected cases from the analysis (Table 2; see also below). Analyzing the age distribution of CARVpositive cases (Figure 3), we found higher detection rates of adenovirus, parainfluenzavirus,

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

respiratory syncytial virus, rhinovirus and influenzavirus-A/B cases in children ≤16 years, while similar rates of human coronavirus-, metapneumovirus- and M. pneumoniae were detected in children and adults (Supplementary Table 3). Moreover, adenovirus-positive patients were significantly younger than patients testing positive for other CARVs or SARS-CoV-2 (P<0.001; **Table 3**). Among adults (1554/1816; 85.5%), no significant age differences were observed for patients testing positive for any CARV, but patients being positive for SARS-CoV-2 tended to be older than patients testing positive for any other CARV (P<0.01; Figure 3, Supplementary Table 4). Among CARV positive cases, co-infections with two or three CARVs occurred in 55 (3%) and five (0.3%) patients, respectively (**Table 4**). Rhinovirus and adenovirus as well as rhinovirus and respiratory syncytial virus co-infections were almost exclusively found in children ≤2 years. In 17 (0.9%) of 1816 patients (15 adults aged 30 to 93 years, 2 children), SARS-CoV-2 was detected together with at least one other CARV, which consisted of a single pathogen in 15 cases, namely rhinovirus (n=5), human coronaviruses (n=5), parainfluenzavirus (n=3) and influenzavirus (n=2), and more than one CARV detection in 2 cases (Table 4). Overall, CARV detection was associated with a high negative predictive value of 98.1% for SARS-CoV-2 infection. The negative predictive value for SARS-CoV-2 infection was higher in CARV-positive children (99.0%; ≤16 years) than adults (97.1%; >16 years). Conversely, a negative multiplex-NAT result after the first detected SARS-CoV-2 case was associated with a rapidly increasing likelihood to be positively tested for SARS-CoV-2 from 1% in calendar week 9 to 48% in calendar week 13 (Figure 2).

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

**Discussion** The SARS-CoV-2 pandemic hit Europe in winter 2020, during which a number of circulating CARVs are at their yearly seasonal peak including influenzavirus, respiratory syncytial virus, and human coronaviruses. Our analysis from the start to the peak of the pandemic wave of SARS-CoV-2 in Northwestern Switzerland has three major findings. First, the early pandemic phase until calendar week 10 was dominated by winter CARVs. emphasizing the importance of their rapid and accurate identification due to several reasons: i) significant morbidity and mortality in vulnerable patients (very young, elderly, immunocompromised) [5]; ii) specific antiviral therapy in case of influenzavirus-A/B detection; iii) appropriate infection control and cohorting strategies upon hospital admission; and iv) prevention of unnecessary empiric antibiotic therapy in CARV-positive patients, or treatment adaptation in case of atypical bacterial agents like M. pneumoniae [10-13]. In this early phase, CARV detection was associated with a high negative predictive value of 98.1% for SARS-CoV-2 infection. Second, SARS-CoV-2 almost completely replaced the seasonally circulating CARVs within only 3 weeks' time. During calendar week 12 and 13, SARS-CoV-2 was practically the only respiratory virus leading to a cumulative 48% runner-up position when counting all detected CARVs from January 1st, 2020. This dynamic evolution was also seen when explicitly analyzing NOPS from patients with respiratory illness for whom both CARV- and SARS-CoV-2 testing had been requested. The weekly prevalence revealed a significant increase in SARS-CoV-2 detection rates while the initially increasing CARVs were curtailed. These data suggest the intriguing possibility of competing risks for host infection. Third, diagnosis of SARS-CoV-2 infection was highly reliable being based on three independent molecular tests. Thereby, an independent validation of the WHO-endorsed Egene was provided. Whereas respiratory panel testing is well validated and widely used in tertiary care centers [5, 14, 15], the response to the SARS-CoV-2 pandemic hinges on the performance of a new diagnostic test for a new viral agent, and its communication within a

short turn-around time. To accomplish this task, we prospectively tested all NOPS directly in

parallel with the commercial Roche-E-gene and our Basel-S-gene RT-QNAT. This outstanding opportunity for independent test validation on more than 7600 patients demonstrated high concordance of 97.5% between both assays including 825 (11%) SARS-CoV-2 infections, which could be communicated without further delay to the treating physicians. Importantly, comparison of the Ct-values revealed that the discordance mostly resulted from SARS-CoV-2 loads at the limit of detection. Thus, discordant results became increasingly likely at very low, hence limiting viral loads in the NOPS, most likely reflecting a stochastic distribution of genomes in the analyte.

A limitation of our study is the dependence on the pre-analytic steps of NOPS sampling, especially in the light of the natural course of SARS-CoV-2 infection. We addressed this challenge through repeated instructions and video clips demonstrating the correct use of personal protection equipment, validated swab sets, and defined sampling procedures in dedicated hospital areas. However, late presentation at stages of more advanced disease manifesting in the lower respiratory tract requires testing of respiratory samples from the lower respiratory tract, while this study was restricted to the first diagnostic testing in NOPS. Early testing is clinically and epidemiologically advisable in view of high viral loads detectable already early in the course in exposed pre-symptomatic and in oligo-symptomatic persons [16, 17].

Since our diagnostic laboratory is serving both regional tertiary care centers for adults and children, we examined the age distribution of SARS-CoV-2 and CARV infection. Indeed, patients testing positive for adenovirus and respiratory syncytial virus were significantly younger and more likely to be children below the age of 5 years, among whom SARS-CoV-2 infection remained rare, in line with other studies [18, 19]. Although SARS-CoV-2 positive adults were older than patients testing positive for CARVs, the median age of >40 years in CARV-positive patients suggests that similar adult populations were at risk for established CARVs or for the novel SARS-CoV-2.

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

Our study also provides intriguing observations regarding the epidemiology of SARS-CoV-2 in its capacity to replace circulating CARVs among adults. Notably, co-infection rates of CARVs with SARS-CoV-2 were rather low as reported here and by others [8], suggesting a competitive infection situation. It is presently unclear whether virus properties such as higher infectiousness, facilitated transmission, or increased host susceptibility are the decisive factors conferring significant advantages to the novel SARS-CoV-2 in this first wave of the pandemic. Regarding the infectiousness of SARS-CoV-2, our data provide independent evidence for very high viral loads in the order of 1 – 100 million copies per milliliter transport medium. Even if these high numbers only carry 1000-fold lower infectious units, the infectious activity remains high in the patients' respiratory secretions. Notably, similarly high viral loads have also been described for CARVs including influenza or respiratory syncytial virus [5, 20-22]. Regarding transmission, SARS-CoV-2 is thought to behave less like influenzaviruses spreading significantly by aerosols [23, 24], but rather like respiratory syncytial virus spreading by droplets, contaminated surfaces and hands [25, 26]. However, aerosolization of SARS-CoV-2 may also play a role, especially when associated with highvelocity air streams during sneezing, singing and medical procedures [27-29]. Finally, increased susceptibility of the human host to infection by this novel, presumably zoonotic coronavirus remains, but is a difficult to estimate factor at this time. Already the first reports from China in January 2020 indicated that SARS-CoV-2 is well adapted to the human host [30]. Unlike SARS-CoV-1, SARS-CoV-2 is easily transmitted from human to human already before the start of symptoms, hence facilitating the pandemic spread [17, 31, 32]. However, SARS-CoV-2 seems to be susceptible to type-1 interferons [33], and induces high amounts of interleukin-6 through excessive macrophage activation upon progression to viral pneumonia, which has become a clinically relevant target of CoVID-19 treatment [34]. What could be the underlying mechanisms for an increased susceptibility to SARS-CoV-2 infection competitively replacing established CARVs in a mostly adult population? Hand

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

washing, social distancing and lock-down measure would be predicted to affect CARVs and SARS-CoV-2 alike, but were not yet sufficiently effective to prevent the upswing of the pandemic wave. We hypothesize that the decisive factors may be the differential net response of the host to virus-induced unspecific innate immunity on the one hand and to virus-specific adaptive immune memory on the other hand. CARV infections are known to cause an innate immune response including type-1 interferons, which reduces the risk of coinfection by other viruses including SARS-CoV-2 [35, 36]. Since adults have been repeatedly exposed to CARVs in the past, their CARV-specific immune memory may not be high enough to prevent symptomatic CARV re-infection, but is readily boosted upon re-exposure. hence limiting CARV replication and the associated inflammation elicited by innate immunity. We propose that thereby the semi-immune mostly adult host population becomes available for SARS-CoV-2 infection. Since SARS-CoV-2 is novel having little, if any, specific immune memory, its replication is prolonged, evoking pronounced inflammation, delaying infection by other circulating CARVs, extending transmission periods and shifting the epidemiologic curve in favor of this novel agent. This differential net response of virus-induced unspecific innate immunity and virus-specific adaptive immune memory may also contribute to the puzzling lower infection rates seen in small children, who typically replicate CARVs in high frequency and high levels, hence interfering with SARS-CoV-2. However, CARVs may differ in their propensity to interfere and may be low for rhinovirus. Indeed, 46 (60%) of 77 coinfections involved rhinovirus. Although other (co-)factors cannot be excluded, our hypothesis will be testable by analyzing, whether or not vaccines to CARVs and/or to SARS-CoV-2 change this competitive epidemiologic risk. Possibly, CARV interference will be reduced during the summer months putting younger age populations at risk for the pandemic SARS-CoV-2. In conclusion, circulating CARVs were dominant during the first phase of the CoVID-19 pandemic, but rapidly replaced within 2 weeks by SARS-CoV-2. A comprehensive testing

strategy covering SARS-CoV-2 and CARVs is central to infection control and clinical

management. Epidemiologic determinants of the competitive infection risk between established CARVs and the novel SARS-CoV-2 require further studies including unspecific innate immune interference and virus-specific adaptive immune memory.

Main Body Word Count: 3212

Acknowledgements

358

359

360

361

We thank the biomedical technicians of the Clinical Virology Division and the Clinical

Bacteriology and Mycology Division, Laboratory Medicine, University Hospital Basel, Basel,

Switzerland for expert help and assistance.

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

Figure Legend Figure 1. Comparison of cycling thresholds in the S-gene, E-gene and N-gene RT-QNATs and SARS-CoV-2 loads. NOPS were submitted for routine testing with the S-gene and E-gene RT-QNATs (n=7663). Samples with concordant positive or discordant results were subsequently tested with the inhouse N-gene RT-QNAT. A. Cycling thresholds of concordant positive and discordant samples are displayed (median, 25<sup>th</sup> and 75<sup>th</sup> percentiles; n=7663). B. SARS-CoV-2 loads and number of cases determined with the S-gene RT-QNAT in positive samples (median, 25<sup>th</sup> and 75<sup>th</sup> percentiles; n=927). Figure 2. SARS-CoV-2 and CARV epidemiology during the beginning of the epidemic spread from January to March 2020. HAdV, human adenoviruses; HCoV, human coronavirus (-229E, -OC43, -NL63, and -HKU1); IV-A/B, influenza virus A and B; HMPV, human metapneumovirus; HPIV, human parainfluenzavirus (1 to 4); HRV, human rhinovirus; HRSV, human respiratory syncytial virus; M. pne, Mycoplasma pneumoniae; SARS-CoV-2, severe acute respiratory syndrome coronavirus. A. Weekly SARS-CoV-2 (n=8592) and CARV (n=2394) prevalence in symptomatic children and adults. B. Weekly prevalence of cumulated SARS-CoV-2 (n=8592) and CARV (N=2394) cases in symptomatic children and adults (bar chart), cumulated SARS-CoV-2 and CARV cases by calendar week 13 (pie chart). C. Weekly SARS-CoV-2 and CARV prevalence in NOPS tested in parallel (n=1816), cumulated SARS-CoV-2 and CARV cases by calendar week 13 (pie chart).

Figure 3. Age distribution of CARV and SARS-CoV-2 positive patients.

NOPS were analyzed in parallel for different CARVs with multiplex NAT and SARS-CoV-2 with the RT-QNAT assays. Patient age of CARV or SARS-CoV-2 positive patients is displayed (median, 25<sup>th</sup> and 75<sup>th</sup> percentiles; n=1816), and compared using Mann–Whitney U test (Table 3; Supplementary Table 4).

392 References 393 1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 394 2019. New Engl J Med 2020; 382: 727. 395 2. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus 396 of probable bat origin. Nature 2020; 579: 270. 397 3. Coronaviridae Study Group of the International Committee on Taxonomy of V. The species 398 Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it 399 SARS-CoV-2. Nat Microbiol 2020; 5: 536. 400 WHO. Coronavirus disease (COVID-19) Situation Report-119. World Health Organization 4. 401 2020. 402 5. Ison MG, Hirsch HH. Community-Acquired Respiratory Viruses in Transplant Patients: 403 Diversity, Impact, Unmet Clinical Needs. Clin Microbiol Rev 2019; 32: e00042-19. 404 6. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus 405 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From 406 the Chinese Center for Disease Control and Prevention. JAMA 2020; doi: 407 10.1001/jama.2020.2648. 408 7. Nicastri E, D'Abramo A, Faggioni G, et al. Coronavirus disease (COVID-19) in a 409 paucisymptomatic patient: epidemiological and clinical challenge in settings with limited 410 community transmission, Italy, February 2020. Eur Surveill 2020; 25: 2000230. 411 8. Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of Co-infection Between SARS-CoV-2 412 and Other Respiratory Pathogens. JAMA 2020; 323:2085. 413 9. Leuzinger K, Naegele K, Schaub S, Hirsch HH. Quantification of plasma BK polyomavirus 414 loads is affected by sequence variability, amplicon length, and non-encapsidated viral DNA 415 genome fragments. J Clin Virol 2019; 121: 104210. 416 10. Beckmann C, Hirsch HH. Comparing Luminex NxTAG-Respiratory Pathogen Panel and 417 RespiFinder-22 for multiplex detection of respiratory pathogens. J Med Virol 2016; 88: 1319. 418 11. Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical Practice Guidelines by the Infectious 419 Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and

Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis 2019; 68: 1.

421 12. Krantz EM, Zier J, Stohs E, et al. Antibiotic Prescribing and Respiratory Viral Testing for 422 Acute Upper Respiratory Infections Among Adult Patients at an Ambulatory Cancer Center. 423 Clin Infect Dis 2020; 70: 1421. 424 13. Dierig A, Hirsch HH, Decker ML, Bielicki JA, Heininger U, Ritz N. Mycoplasma pneumoniae 425 detection in children with respiratory tract infections and influence on management - a 426 retrospective cohort study in Switzerland. Acta paediatrica 2020; 109: 375. 427 14. Charlton CL, Babady E, Ginocchio CC, et al. Practical Guidance for Clinical Microbiology 428 Laboratories: Viruses Causing Acute Respiratory Tract Infections. Clin Infect Dis 2019; 32: 1. 429 15. Hirsch HH. Spatiotemporal Virus Surveillance for Severe Acute Respiratory Infections in 430 Resource-limited Settings: How Deep Need We Go? Clin Infect Dis 2019; 68: 1126. 431 16. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of 432 Infected Patients. New Engl J Med 2020; 382: 1177. 433 17. Pan X, Chen D, Xia Y, et al. Asymptomatic cases in a family cluster with SARS-CoV-2 434 infection. Lancet Infect Dis 2020; 20: 410. 435 18. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel 436 coronavirus in Wuhan, China. Lancet (London, England) 2020; 395: 497. 437 19. Novel Coronavirus Pneumonia Emergency Response Epidemiology T. The epidemiological 438 characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) - China, 2020. 439 Vol. 2. China CDC Weekly, 2020; 113. 440 20. Chemaly RF, Dadwal SS, Bergeron A, et al. A phase 2, randomized, double-blind, placebo-441 controlled trial of presatovir for the treatment of respiratory syncytial virus upper respiratory 442 tract infection in hematopoietic-cell transplant recipients. Clin Infect Dis 2019; ciz1166 443 21. Khanna N, Widmer AF, Decker M, et al. Respiratory syncytial virus infection in patients with 444 hematological diseases: single-center study and review of the literature. Clin Infect Dis 2008; 445 46: 402. 446 22. Khanna N, Steffen I, Studt JD, et al. Outcome of influenza infections in outpatients after 447 allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2009; 11: 100. 448 23. Cowling BJ, Ip DK, Fang VJ, et al. Aerosol transmission is an important mode of influenza A

virus spread. Nat Commun 2013; 4: 1935.

- 450 24. Tellier R. Review of aerosol transmission of influenza A virus. Emerg Infect Dis 2006; 12:
- 451 1657.
- 452 25. Falsey AR, Formica MA, Walsh EE. Diagnosis of respiratory syncytial virus infection:
- 453 comparison of reverse transcription-PCR to viral culture and serology in adults with
- respiratory illness. J Clin Microbiol **2002**; 40: 817.
- 455 26. Gerna G, Campanini G, Rognoni V, et al. Correlation of viral load as determined by real-time
- 456 RT-PCR and clinical characteristics of respiratory syncytial virus lower respiratory tract
- infections in early infancy. J Clin Virol **2008**; 41: 45.
- 458 27. Zhan M, Qin Y, Xue X, Zhu S. Death from Covid-19 of 23 Health Care Workers in China. New
- 459 Engl J Med **2020**; 382: 2267.
- 460 28. Ong SWX, Tan YK, Chia PY, et al. Air, Surface Environmental, and Personal Protective
- 461 Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
- 462 CoV-2) From a Symptomatic Patient. JAMA **2020**; 323: 1610.
- 463 29. Hamner L, Dubbel P, Capron I, et al. High SARS-CoV-2 Attack Rate Following Exposure at a
- Choir Practice Skagit County, Washington, March 2020. MMWR Morb Mortal Wkly Rep
- **2020**; 69: 606.
- 466 30. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel
- 467 Coronavirus-Infected Pneumonia. New Engl J Med 2020; 382: 1199.
- 468 31. Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of COVID-19.
- 469 JAMA **2020**; 323: 1406.
- 470 32. Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 Infections and
- 471 Transmission in a Skilled Nursing Facility. New Engl J Med **2020**; 382: 2081.
- 472 33. Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N. Type 1 interferons as a
- potential treatment against COVID-19. Antivir Res **2020**; 178: 104791.
- 474 34. Chen X, Zhao B, Qu Y, et al. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely
- 475 correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients.
- 476 Clin Infect Dis **2020**; ciaa449.
- 477 35. Compagno F, Braunacker-Mayer L, Khanna N, et al. Comparing viral respiratory tract
- infections in symptomatic children and adults: Multiplex NAT from 2010 2015 (EP0641).
- 479 ECCMID 2017. Vienna, Austria **2017**.

480 36. Mesev EV, LeDesma RA, Ploss A. Decoding type I and III interferon signalling during viral

infection. Nat Microbiol 2019; 4: 914.

**Table 1.** Patients' demographics of NOPS tested for SARS-CoV-2 between calendar week 11 and 13 (Mann–Whitney U test; n=7663).

		A.II	SARS-CoV-2	SARS-CoV-2	
		All	positive	negative	p-value
Patients' Demographics	Patients (N,%)	7663	930 (12%)	6733 (88%)	-
	Age (median, IQR)	43	49	43	
		25 <sup>th</sup> : 31	25 <sup>th</sup> : 34	25 <sup>th</sup> : 30	.0.004
		75 <sup>th</sup> : 58	75 <sup>th</sup> : 62	75 <sup>th</sup> : 57	p<0.001
		IQR: 27	IQR: 28	IQR: 27	
	Gender (male, %)	3407 (44%)	458 (49%)	2949 (44%)	P=0.002
	Pediatric patients (≤16 years)	354 (5%)	14 (4%)	340 (96%)	p<0.001
Primary Care		5697 (74%)	774 (83%)	4923 (73%)	-
Secondary or Tertiary Care		1966 (26%)	156 (17%)	1810 (27%)	-
	Medical Care Unit	136 (7%)	11 (7%)	125 (7%)	-
	Intensive Care Unit	67 (3%)	8 (5%)	59 (3%)	-
	Pneumology Unit	45 (2%)	1 (1%)	44 (2%)	-

**Table 2.** Comparison of SARS-CoV-2 and any CARV infection in adult and pediatric patients using Mann–Whitney U test (n=1816; excluding human rhinovirus only cases n=1671).

Pathogen	Testresult	Α	ge	p-value	
raulogen	estresuit	≤16 years	>16 years	_ p-value	
SARS-CoV-2	Positive	5 (2%)	143 (9%)	P<0.001	
	Negative	257 (98%)	1411 (91%)		
Any CARV <sup>1</sup>	Positive	166 (63%)	479 (31%)	P<0.001	
	Negative	96 (37%)	1075 (69%)		
SARS-CoV-2 or	Positive	169 (65%)	606 (39%)	P<0.001	
any CARV	Negative	93 (35%)	948 (61%)		
SARS-CoV-2 or	Positive	127 (65%)	503 (39%)	P<0.001	
CARV					
(excluding rhinovirus)	Negative	93 (35%)	948 (61%)		

<sup>&</sup>lt;sup>1</sup>Any CARV includes: human adenoviruses, human coronavirus (-229E, -OC43, -NL63, and -HKU1), influenza virus A and B, human metapneumovirus, human parainfluenzavirus (1 to 4), human rhinovirus, human respiratory syncytial virus and the atypical bacterial agent M. pneumoniae

**Table 3.** Pairwise comparison of patient age in SARS-CoV-2 or CARV positive patients (Mann–Whitney U test; brackets indicate the p-value after Bonferroni correction; n=1816).

	110 41/	LIDIV	LIDCV	LIDV	N/ A/D	110-1/	LIMEN	Mana	SARS-
	HAdV	HPIV	HRSV	HRV	IV-A/B	HCoV	HMPV	M.pne	CoV-2
HAdV		0.05	0.2	0.0007	7.9e-08	1.3e-07	5.4e-07	3.9e-05	1.7e-14
1 1/10 1		[0.4]	[1]	[0.005]	[6.4e-07]	[1.0e-06]	[4.3e-06]	[0.0003]	[1.4e-13]
HPIV	0.05		0.7	0.5	0.03	0.02	0.02	0.05	2.4e-05
	[0.4]		[1]	[1]	[0.2]	[0.2]	[0.1]	[0.4]	[0.0002]
HRSV	0.2	0.7		0.08	0.0004	0.0003	0.0002	0.01	9.9e-11
	[1]	[1]		[0.6]	[0.003]	[0.003]	[0.001]	[80.0]	[7.9e-10]
HRV	0.0007	0.5	0.08		0.005	0.003	0.0007	0.06	5.3e-14
1	[0.005]	[1]	[0.6]		[0.04]	[0.02]	[0.006]	[0.5]	[4.2e-13]
IV-A/B	7.9e-08	0.03	0.0004	0.005		0.4	0.09	0.7	1.2e-09
	[6.4e-07]	[0.2]	[0.003]	[0.04]		[1]	[0.7]	[1]	[9.9e-09]
HCoV	1.3e-07	0.02	0.0003	0.003	0.4		0.3	0.9	0.3
	[1.0e-06]	[0.2]	[0.003]	[0.02]	[1]		[1]	[1]	[1]
HMPV	5.4e-07	0.02	0.0002	0.0007	0.09	0.3		0.4	0.02
	[4.3e-06]	[0.1]	[0.001]	[0.006]	[0.7]	[1]		[1]	[0.1]
M.pne	3.9e-05	0.05	0.01	0.06	0.7	0.9	0.4		0.9
	[0.0003]	[0.4]	[80.0]	[0.5]	[1]	[1]	[1]		[1]
SARS-	1.7e-14	2.4e-05	9.9e-11	5.3e-14	1.2e-09	0.3	0.02	0.9	
CoV-2	[1.4e-13]	[0.0002]	[7.9e-10]	[4.2e-13]	[9.9e-09]	[1]	[0.1]	[1]	

P>0.05
P<0.05

HAdV, human adenoviruses; HCoV, human coronavirus (-229E, -OC43, -NL63, and -HKU1);

IV-A/B, influenza virus A and B; HMPV, human metapneumovirus; HPIV, human parainfluenzavirus (1 to 4);

 $HRV, \ human\ rhinovirus;\ HRSV,\ human\ respiratory\ syncytial\ virus;\ M.\ pne,\ Mycoplasma\ pneumoniae;$ 

SARS-CoV-2, severe acute respiratory syndrome coronavirus

**Table 4.** Patients with more than one positive SARS-CoV-2 or CARV detection (n=1816).

CARVs detected	Number of	Age ≤2 years	Age ≤5 years	Age ≤16 years	Age >16 years	
OAKVS detected	patients	Age 32 years	Age 20 years	Age 210 years		
SARS-CoV-2 and HCoV	5	-	-	-	5	
SARS-CoV-2 and HRV	5	-	1	1	4	
SARS-CoV-2 and HPIV	3	-	-	-	3	
SARS-CoV-2 and IV-A	2	-	-	-	2	
SARS-CoV-2 and HRV and HAdV	1	-	-	-	1	
SARS-CoV-2 and HRV and HRSV and				_		
HPIV	1	-	1	1	-	
HRV and HAdV	11	8	10	10	1	
HRV and HCoV	6	2	2	3	3	
HRV and IV-A/B	5	1	1	2	3	
HRV and HRSV	5	3	4	4	1	
HRV and HPIV	3	-	2	2	1	
HRV and HMPV	2	1	1	1	1	
HRV and M. pne	1	-	-	-	1	
HRV and B. para	1	-	1	1	-	
HRV and HCoV and IV-A/B	1	-	-	1	-	
HRV and HCoV and HAdV	1	-	1	1	-	
HRV and HRSV and IV-A/B	1	-	1	1	-	
HRV and HPIV and HAdV	1	-	-	1	-	
HCoV and IV-A/B	3	-	-	-	3	
HCoV and HRSV	3	2	2	2	1	
HCoV and HPIV	2	-	-	-	2	
HCoV and HMPV	2	1	1	1	1	
HCoV and HAdV	2	1	2	2	-	
HCoV and HMPV and M. pne	1	-	1	1	-	
HAdV and HRSV	2	-	1	1	1	
HAdV and IV-A/B	1	-	-	-	1	
HAdV and B. para	1	-	-	1	=	
HAdV and M. pne	1	-	-	-	1	
HAdV and HMPV	1	1	1	1	-	
IV-A/B and HRSV	2	1	1	2	-	
IV-A/B and HMPV	1	-	-	-	1	
Total	77	21	34	40	37	

B. per, Bordetella pertussis; B. para, Bordetella parapertussis; HAdV, human adenoviruses; HCoV, human coronavirus (-229E, -OC43, -NL63, and -HKU1); hMPV, human metapneumovirus; HPIV, human parainfluenzavirus (1 to 4); HRV, human rhinovirus; IV-A/B, influenza virus A and B; M. pne, Mycoplasma pneumoniae; SARS-CoV-2, severe acute respiratory syndrome coronavirus







Figure 2










Table S1. Forward primers, reverse primers and probes of the SARS-CoV-2 RT-QNATs.

Gene	Primer/Probe	Sequence (5'→ 3')	Position <sup>1</sup>
Spike glycoprotein	Forward primer	GGTTATCTTCAACCTAGGAC	22364 - 22383
(Basel-SCoV2-S-111bp)	Reverse primer	ATTTCAACGTACACTTTGTT	22475 - 22456
	Probe	TGTAGACTGTGCACTTGACCCTCTCTC	22426 - 22452
Nucleocapsid	Forward primer	ATCGGTAATTATACAGTTTCC	28119 - 28139
(Basel-SCoV2-N-98bp)	Reverse primer	AGTCTTCATAGAACGAACAA	28215 - 28196
	Probe	TGCCAGGAACCTAAATTGGGTAGTCT	28161 - 28186

<sup>&</sup>lt;sup>1</sup> Position according to SARS-CoV-2 isolate Wuhan-Hu-1 (acc. no. NC\_045512.2)

**Table S2.** Frequency of single nucleotide polymorphisms in the laboratory-developed SARS-CoV-2 spike glycoprotein (Basel-SCoV2-S-111bp) and nucleocapsid (Basel-SCoV2-N-98bp) RT-QNAT target regions.

Gene	Position <sup>1</sup>	SNP <sup>2</sup>		Frequency (%)			
Gene	Position	SNP-	±150bp <sup>3</sup>	±100bp <sup>3</sup>	±5bp³		
	22224	$C\toG$	0.03%4	-	-		
Spike glycoprotein (Basel-SCoV2-S-111bp)	22303	$T\toG$	0.03%4	0.03%4	-		
( ) )	22432	$C\toT$	0.03%5	0.03%5	0.03%5		
Nucleocapsid	28077	$G\toC$	0.1%4	0.1%4	-		
(Basel-SCoV2-S-98bp)	28144	$T\toC$	0.3%6	0.3%6	0.3%6		

<sup>&</sup>lt;sup>1</sup> Position according to SARS-CoV-2 isolate Wuhan-Hu-1 (acc. no. NC\_045512.2)

<sup>&</sup>lt;sup>2</sup> Single nucleotide polymorphism (SNP) and frequency among 3323 SARS-CoV-2 (taxid: 2697049) spike glycoprotein-gene and nucleocapsid-gene GenBank and GISAID sequences (accessed on 20<sup>th</sup> of April 2020) compared to SARS-CoV-2 as reference genome (acc. no. NC\_045512.2).

<sup>&</sup>lt;sup>3</sup> RT-QNAT target region ±150bp, ±100bp and ±5bp

<sup>&</sup>lt;sup>4</sup> SNP outside the RT-QNAT target region

<sup>&</sup>lt;sup>5</sup> SNP in the probe-binding site

<sup>&</sup>lt;sup>6</sup> SNP in the RT-QNAT target region, but not in a primer/probe-binding site

**Table S3.** Comparison of SARS-CoV-2 and any CARV infection and the age distribution of adult and pediatric patients using Mann–Whitney U test (n=1816).

	≤16 ye	ars	>16 ye	ars		
	(N=26	62)	(N=15	54)		
Pathogen	Number of positive	Age	Number of positive	Age	p-value	
	cases	Distribution	cases	Distribution		
		Median: 2		Median: 40		
		25 <sup>th</sup> : 1		25 <sup>th</sup> : 34		
HAdV	27 (10%)	75 <sup>th</sup> : 4	16 (1%)	75 <sup>th</sup> : 51	P<0.001	
		IQR: 3		IQR: 17		
		Median: 4		Median: 50		
		25 <sup>th</sup> : 3		25 <sup>th</sup> : 24		
HPIV	9 (3%)	75 <sup>th</sup> : 6	11 (1%)	75 <sup>th</sup> : 62	P=0.02	
		IQR: 3		IQR: 39		
		Median: 1		Median: 42		
		25 <sup>th</sup> : 1		25 <sup>th</sup> : 32		
HRSV	29 (11%)	75 <sup>th</sup> : 4	36 (2%)	75 <sup>th</sup> : 66	P<0.001	
		IQR: 3		IQR: 34		
		Median: 3		Median: 44		
		25 <sup>th</sup> : 1.5		25 <sup>th</sup> : 36		
HRV	71 (27%)	75 <sup>th</sup> : 4.5	119 (8%)	75 <sup>th</sup> : 67	P<0.001	
		IQR: 3.0		IQR: 31		
		Median: 6		Median: 46		
		25 <sup>th</sup> : 3		25 <sup>th</sup> : 32	P=0.03	
IV-A/B	34 (13%)	75 <sup>th</sup> : 9	135 (9%)	75 <sup>th</sup> : 62		
		IQR: 6		IQR: 30		
		Median: 3		Median: 49		
		25 <sup>th</sup> : 1		25 <sup>th</sup> : 34		
HCoV	18 (7%)	75 <sup>th</sup> : 4	100 (6%)	75 <sup>th</sup> : 63	P=0.79	
		IQR: 3		IQR: 29		
		Median: 4		Median: 58		
		25 <sup>th</sup> : 1		25 <sup>th</sup> : 38		
HMPV	16 (6%)	75 <sup>th</sup> : 4	63 (4%)	75 <sup>th</sup> : 76	P=0.13	
		IQR: 3		IQR: 38		
		Median: 10		Median: 47		
	25 <sup>th</sup> : 7		25 <sup>th</sup> : 38			
M. pne	3 (1%)	75 <sup>th</sup> : 11	20 (1%)	75 <sup>th</sup> : 55	P=0.85	
		IQR: 4		IQR:18		
		Median: 2		Median: 61		
		25 <sup>th</sup> : 1		25 <sup>th</sup> : 43		
SARS-CoV-2	5 (2%)	75 <sup>th</sup> : 3	143 (9%)	75 <sup>th</sup> : 75	P<0.001	
		IQR: 2		IQR: 32		

HAdV, human adenoviruses; HCoV, human coronavirus (-229E, -OC43, -NL63, and -HKU1);

IV-A/B, influenza virus A and B; HMPV, human metapneumovirus; HPIV, human parainfluenzavirus (1 to 4);

HRV, human rhinovirus; HRSV, human respiratory syncytial virus; M. pne, Mycoplasma pneumoniae;

SARS-CoV-2, severe acute respiratory syndrome coronavirus

**Table S4.** Pairwise comparison of patient age in SARS-CoV-2 or CARV positive adults of >16 years (Mann–Whitney U test; brackets indicate the p-value after Bonferroni correction; n=1554).

	114 07	LIDIV/	LIDOV	LID) /	D / A /D	110.17	LIMP) (		SARS-
	HAdV	HPIV	HRSV	HRV	IV-A/B	HCoV	HMPV	M.pne	CoV-2
HAdV		0.7	0.5	0.2	0.3	0.2	0.02	0.4	0.001
TIAGV		[1]	[1]	[1]	[1]	[1]	[0.2]	[1]	[0.01]
HPIV	0.7		0.6	0.4	0.6	0.6	0.2	0.9	0.07
1	[1]		[1]	[1]	[1]	[1]	[1]	[1]	[0.5]
HRSV	0.5	0.6		0.5	0.9	0.9	0.08	0.9	0.001
	[1]	[1]		[1]	[1]	[1]	[0.6]	[1]	[0.01]
HRV	0.2	0.4	0.5		0.4	0.6	0.06	0.6	0.001
111.	[1]	[1]	[1]		[1]	[1]	[0.4]	[1]	[0.01]
IV-A/B	0.3	0.6	0.9	0.4		0.8	0.01	0.7	1.5e-05
17,75	[1]	[1]	[1]	[1]		[1]	[0.08]	[1]	[0.0001]
HCoV	0.2	0.6	0.9	0.6	0.8		0.02	0.6	0.0002
11001	[1]	[1]	[1]	[1]	[1]		[0.2]	[1]	[0.002]
HMPV	0.02	0.2	0.08	0.06	0.01	0.02		0.04	0.7
1	[0.2]	[1]	[0.6]	[0.4]	[80.0]	[0.2]		[0.3]	[1]
M.pne	0.4	0.9	0.9	0.6	0.7	0.6	0.04		0.005
	[1]	[1]	[1]	[1]	[1]	[1]	[0.3]		[0.04]
SARS-	0.001	0.07	0.001	0.001	1.5e-05	0.0002	0.7	0.005	
CoV-2	[0.01]	[0.5]	[0.01]	[0.01]	[0.0001]	[0.002]	[1]	[0.04]	

P>0.05
P<0.05


HAdV, human adenoviruses; HCoV, human coronavirus (-229E, -OC43, -NL63, and -HKU1);

IV-A/B, influenza virus A and B; HMPV, human metapneumovirus; HPIV, human parainfluenzavirus (1 to 4);


HRV, human rhinovirus; HRSV, human respiratory syncytial virus; M. pne, Mycoplasma pneumoniae;

SARS-CoV-2, severe acute respiratory syndrome coronavirus


A Complete genome sequences of human coronaviruses



B Spike glycoprotein gene sequences of human coronaviruses



C Nucleocapsid gene sequences of human coronaviruses



# Figure S1. Phylogenetic analysis using complete SARS-CoV-2 genome sequences, the S-gene and N-gene sequences.

Divergences were estimated by the Jukes-Cantor method and neighbor-joining trees were constructed with the CLC Genomic Workbench software.

- A. Phylogenetic analysis of complete SARS-CoV-2 genome sequences of 29'900 nucleotides (nt) in length available in the NCBI-GenBank and GISAID database (accessed on 20th of April; n=3323).
- B. Phylogenetic analysis of the S-gene region of 3'822 nt (corresponds to nucleotide positions 21563 to 25384 in the SARS-CoV-2 reference genome [acc. no. NC 045512.2]; n=3323).
- C. Phylogenetic analysis of the N-gene region of 366 nt (corresponds to nucleotide positions 27894 to 28259 in the SARS-CoV-2 reference genome [acc. no. NC\_045512.2]; n=3323).

# Figure S1. Phylogenetic analysis using complete SARS-CoV-2 genome sequences, the S-gene and N-gene sequences.

Divergences were estimated by the Jukes-Cantor method and neighbor-joining trees were constructed with the CLC Genomic Workbench software.

- A. Phylogenetic analysis of complete SARS-CoV-2 genome sequences of 29'900 nucleotides (nt) in length available in the NCBI-GenBank and GISAID database (accessed on 20th of April; n=3323).
- B. Phylogenetic analysis of the S-gene region of 3'822 nt (corresponds to nucleotide positions 21563 to 25384 in the SARS-CoV-2 reference genome [acc. no. NC 045512.2]; n=3323).
- C. Phylogenetic analysis of the N-gene region of 366 nt (corresponds to nucleotide positions 27894 to 28259 in the SARS-CoV-2 reference genome [acc. no. NC\_045512.2]; n=3323).




Figure S2. SARS-CoV-2 testing flowchart.

NOPS were tested in parallel with the in-house S-gene and the commercial E-gene RT-QNATs (n=7663). Samples with concordant positive or discordant results were subsequently tested with the in-house N-gene RT-QNAT. pos, positive; neg, negative.